GlassScriptPhysician profile
Chelsea Thompson
NPI 1992454565
$746.80
in general payments reported to CMS, 2019-2025
22 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.40 · 2023: $188 · 2024: $205 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $161.13 | 2022-2025 | |
| Pfizer INC. | $74.84 | 2022-2025 | |
| Abbvie INC. | $65.46 | 2023-2025 | Creon, Linzess |
| Sanofi-Aventis U.S. LLC | $42.45 | 2024 | |
| Exact Sciences Corporation | $41.57 | 2025 | Cologuard Collection Kit |
| Kvk-Tech, INC. | $40.56 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $37.56 | 2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.53 | 2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $33.97 | 2023-2024 | Xarelto |
| Corcept Therapeutics | $21.38 | 2025 | Korlym |
| Stryker Corporation | $21.35 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Insulet Corporation | $20.99 | 2023 | Omnipod |
| Alkermes, INC. | $20.11 | 2025 | Vivitrol |
| Novo Nordisk INC | $19.37 | 2024 | |
| Boston Scientific Corporation | $19.08 | 2023 | Watchman Flx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $16.56 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $15.25 | 2023 | Bexsero, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $15.05 | 2025 | Auvelity |
| Amgen INC. | $14.45 | 2025 | Repatha, Otezla |
| Lilly USA, LLC | $12.35 | 2022 | |
| Cvrx, INC. | $11.19 | 2024 | Barostim Neo System |
| Phathom Pharmaceuticals, INC. | $7.60 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.